Q-omics provides the consensus-scored WDR93 profile across patient tissues and cancer cell-line models. WDR93 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, WDR93 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, WDR93 RNA expression shows 19,212 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight BRCA, KICH, and KIRP as cancer lineages where WDR93 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WDR93 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WDR93 survival associations across molecular data types. WDR93 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WDR93 RNA expression–survival associations across cancer types. High WDR93 expression shows unfavorable associations in LGG, CHOL and LIHC, but favorable associations in BRCA, KIRP and UCS. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for WDR93 RNA expression.
This table summarizes WDR93 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for WDR93. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WDR93 shows lower tumor expression in KICH, THCA, LUSC and LUAD and higher tumor expression in BLCA and CHOL. The KICH box plot shows higher WDR93 RNA expression in normal versus tumor tissue (log2 FC = −1.200, t-test p < 0.001).
This table shows molecular features associated with WDR93 in patient tissues and cancer cell lines. In patient samples, WDR93 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, WDR93 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
